INVESTOR DEADLINE APPROACHING: Robbins Geller Rudman & Dowd LLP Announces that Constellation Brands, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
SAN DIEGO, April 14, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Constellation Brands, Inc. (NYSE: STZ) securities between April 11, 2024 and January 8, 2025, both dates inclusive (the 'Class Period'), have until Monday, April 21, 2025 to seek appointment as lead plaintiff of the Constellation Brands class action lawsuit. Captioned Meza v. Constellation Brands, Inc., No. 25-cv-06107 (W.D.N.Y.), the Constellation Brands class action lawsuit charges Constellation Brands and certain of Constellation Brands' top executives with violations of the Securities Exchange Act of 1934.
If you suffered substantial losses and wish to serve as lead plaintiff of the Constellation Brands class action lawsuit, please provide your information here:
https://www.rgrdlaw.com/cases-constellation-brands-inc-class-action-lawsuit-stz.html
You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected].
CASE ALLEGATIONS: Constellation Brands produces, imports, markets, and sells beer, wine, and spirits.
The Constellation Brands class action lawsuit alleges that defendants throughout the Class Period: (i) created the false impression that they possessed reliable information pertaining to Constellation Brands' Wine and Spirits business; (ii) failed to improve mix, inventory, and sales execution; and (iii) failed to disclose that investments made in media spend and price promotions as well as adjustments in sales capabilities to support distributor partners had not been as effective as they claimed.
The Constellation Brands class action lawsuit further alleges that on January 10, 2025, Constellation Brands announced its third quarter fiscal year 2025 results, revealing a significant miss on sales performance in the Beer segment and an even steeper miss for the Wine and Spirits segment. On this news, the price of Constellation Brands' stock fell.
THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Constellation Brands securities during the Class Period to seek appointment as lead plaintiff in the Constellation Brands class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Constellation Brands class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Constellation Brands class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Constellation Brands class action lawsuit.
ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud cases. Our Firm has been #1 in the ISS Securities Class Action Services rankings for six out of the last ten years for securing the most monetary relief for investors. We recovered $6.6 billion for investors in securities-related class action cases – over $2.2 billion more than any other law firm in the last four years. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest securities class action recovery ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:
https://www.rgrdlaw.com/services-litigation-securities-fraud.html
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.
Contact:
Robbins Geller Rudman & Dowd LLP
J.C. Sanchez, Jennifer N. Caringal
655 W. Broadway, Suite 1900, San Diego, CA 92101
800-449-4900
[email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
2 Growth Stocks to Stash and 1 to Question
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market's punishment can be swift and severe when trajectories fall. Deciphering which businesses can sustain their high growth rates is a challenge for even the most seasoned professionals, which is why we started StockStory. On that note, here are two growth stocks expanding their competitive advantages and one climbing an uphill battle. One-Year Revenue Growth: +25.3% Founded in 2009 by enterprise software veteran Tom Seibel, (NYSE:AI) provides software that makes it easy for organizations to add artificial intelligence technology to their applications. Why Does AI Fall Short? 15.5% annual revenue growth over the last three years was slower than its software peers Extended payback periods on sales investments suggest the company's platform isn't resonating enough to drive efficient sales conversions Historical operating margin losses point to an inefficient cost structure stock price of $25.72 implies a valuation ratio of 7.4x forward price-to-sales. Dive into our free research report to see why there are better opportunities than AI. One-Year Revenue Growth: +32.3% Founded in 2014 and named after the dreaded first day of the work week, (NASDAQ:MNDY) is a software-as-a-service platform that helps organizations plan and track work efficiently. Why Is MNDY a Good Business? ARR trends over the last year show it's maintaining a steady flow of long-term contracts that contribute positively to its revenue predictability Software is difficult to replicate at scale and results in a best-in-class gross margin of 89.5% Strong free cash flow margin of 30.4% enables it to reinvest or return capital consistently is trading at $305 per share, or 12.7x forward price-to-sales. Is now a good time to buy? Find out in our full research report, it's free. One-Year Revenue Growth: +20% Founded in 2010 and named for a combination of 'docs' and 'proximity', Doximity (NYSE: DOCS) is the leading social network for U.S. medical professionals. Why Should DOCS Be on Your Watchlist? Billings have averaged 23.5% growth over the last year, showing it's securing new contracts that could potentially increase in value over time Well-designed software integrates seamlessly with other workflows, enabling swift payback periods on marketing expenses and customer growth at scale DOCS is a free cash flow machine with the flexibility to invest in growth initiatives or return capital to shareholders At $58.44 per share, Doximity trades at 19x forward price-to-sales. Is now the right time to buy? See for yourself in our comprehensive research report, it's free. Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today for free.
Yahoo
43 minutes ago
- Yahoo
Global Blue Announces NYSE Delisting Proceedings for Warrants
SIGNY, Switzerland, June 11, 2025--(BUSINESS WIRE)--Global Blue Holding AG ("Global Blue") announces that on June 6, 2025, it was notified by the New York Stock Exchange ("NYSE") of its intention to initiate delisting proceedings for Global Blue's warrants, which are listed under the ticker symbol " The NYSE subsequently issued a press release on June 9, 2025, confirming that trading in the warrants will be suspended with immediate effect due to consistently low trading price levels, in accordance with Section 802.01D of the NYSE Listed Company Manual. Global Blue does not intend to appeal this determination. This action relates solely to the company's warrants and does not affect the listing of Global Blue's ordinary shares, which will continue to trade on the NYSE under the ticker symbol "GB". ABOUT GLOBAL BLUE Global Blue is the business partner for the shopping journey, providing technology and services to enhance the experience and drive performance. With over 40 years of expertise, today we connect thousands of retailers, acquirers, and hotels with nearly 80 million consumers across 53 countries, in three industries: Tax Free Shopping, Payments and Post-Purchase solutions. With over 2,000 employees, Global Blue generated €33bn Sales in Store and €508M revenue in FY 2024/25. Global Blue is listed on the New York Stock Exchange. For more information, please visit View source version on Contacts For more information please contact: MEDIA Virginie Alem – Chief Marketing Officer and Chief Operating Officer JapanMail: valem@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
43 minutes ago
- Yahoo
LiveRamp and Walgreens Advertising Group Deliver Business Growth for Advertisers Through Robust Data Collaboration Partnership
WAG advertisers can now accelerate audience creation, activation, and measurement with flexibility and speed SAN FRANCISCO, June 11, 2025--(BUSINESS WIRE)--LiveRamp (NYSE: RAMP), the leading data collaboration partner, today announced it is powering Walgreens Advertising Group's (WAG) clean room solution. The partnership enables WAG, the retail media division of Walgreens, to increase access to its first-party data at speed, scale audience insights, and offer more transparency and control to advertisers. This enables brands to enhance media measurement across all platforms in the digital ecosystem and improve ROI with faster time-to-value. LiveRamp's data collaboration network enables WAG to unlock new insights, accelerate performance, and drive business growth. By strengthening WAG's identity infrastructure and ecosystem connectivity, LiveRamp extends the efficiency of WAG's first-party data solutions to improve personalization capabilities, access data at scale, and deliver real-time campaign performance insights. Using the LiveRamp Clean Room, granular campaign measurement is also possible across offsite publishers and walled gardens. These enhancements bring a multitude of new benefits to WAG advertisers and partners, including: Expanded collaboration based on Walgreens' unique national customer base, including more than 101 million myWalgreens loyalty members who generate billions of signals daily from online, in-store, and delivery activities Self-service access to syndicated and custom audience creation for more personalized targeting across the customer journey, using Walgreens' rich data combined with brands' desired media channels Activation at greater speed and scale across programmatic, walled garden, CTV, social, search, and buy- and sell-side platforms Consolidated measurement to optimize the performance of managed and self-service campaigns with more accurate and granular insights Enhanced interoperability, flexibility, and data governance to minimize the movement of data while collaborating with partners "We're committed to empowering our partners with a transparent, self-service approach that allows them to leverage data on their own terms—with privacy in mind," said Abishake Subramanian, Group Vice President of Customer Marketing and Media Monetization at Walgreens. "Our focus is on investing in leading technologies that enhance data portability, audience scalability, and campaign measurability—while executing responsibly to create more meaningful experiences for Walgreens shoppers. With some of the most integrated and interoperable solutions in the marketplace that support upholding strict privacy protections, partners like LiveRamp play a key role in helping WAG deliver on this vision." "LiveRamp and WAG are helping advertisers get more from their media network investment by improving access, activation, and measurement across any partner or platform with speed and scale," said Vihan Sharma, Chief Revenue Officer at LiveRamp. "WAG is already a highly differentiated offering in retail and healthcare that decouples data and media. Advertisers can now further deepen their customer understanding, improve cross-channel performance, and enhance closed-loop measurement to drive ROI." To learn more about the Walgreens Advertising Group, including the new offerings, visit Uncover the brand-building power of media networks at About Walgreens Founded in 1901, Walgreens ( has a storied heritage of caring for communities for generations, and proudly serves nearly 9 million customers and patients each day across its approximately 8,500 stores throughout the U.S. and Puerto Rico, and leading omni-channel platforms. Walgreens has approximately 220,000 team members, including nearly 90,000 healthcare service providers, and is committed to being the first choice for retail pharmacy and health services, building trusted relationships that create healthier futures for customers, patients, team members and communities. Walgreens is the flagship U.S. brand of Walgreens Boots Alliance, Inc. (Nasdaq: WBA), an integrated healthcare, pharmacy and retail leader. Its retail locations are a critical point of access and convenience in thousands of communities, with Walgreens pharmacists playing a greater role as part of the healthcare system and patients' care teams than ever before. Walgreens Specialty Pharmacy provides critical care and pharmacy services to millions of patients with rare disease states and complex, chronic conditions. About LiveRamp LiveRamp is the leading data collaboration partner, empowering marketers and media owners to deliver exceptional experiences and drive measurable performance everywhere it matters with the world's most powerful data collaboration network. Built on a foundation of strict neutrality, unmatched interoperability, and global scale, LiveRamp enables organizations to maximize measurable outcomes and create lasting business value. Trusted by the world's leading brands, retailers, financial services providers, and healthcare innovators, LiveRamp is shaping the future of responsible data collaboration in an AI-driven, outcomes-focused world. LiveRamp is headquartered in San Francisco, California, with offices worldwide. Learn more at View source version on Contacts Media Contacts Kamara Turnermedia@ Michelle MillsapPR@
